Document Type
Article
Publication Date
7-6-2011
Abstract
BACKGROUND: Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models.
METHODS: We studied Ceacam1 as a regulator of GVHD and GVT after allogeneic bone marrow transplantation (allo-BMT) in mouse models. In vivo, Ceacam1(-/-) T cells caused increased GVHD mortality and GVHD of the colon, and greater numbers of donor T cells were positive for activation markers (CD25(hi), CD62L(lo)). Additionally, Ceacam1(-/-) CD8 T cells had greater expression of the gut-trafficking integrin α(4)β(7), though both CD4 and CD8 T cells were found increased numbers in the gut post-transplant. Ceacam1(-/-) recipients also experienced increased GVHD mortality and GVHD of the colon, and alloreactive T cells displayed increased activation. Additionally, Ceacam1(-/-) mice had increased mortality and decreased numbers of regenerating small intestinal crypts upon radiation exposure. Conversely, Ceacam1-overexpressing T cells caused attenuated target-organ and systemic GVHD, which correlated with decreased donor T cell numbers in target tissues, and mortality. Finally, graft-versus-tumor survival in a Ceacam1(+) lymphoma model was improved in animals receiving Ceacam1(-/-) vs. control T cells.
CONCLUSIONS: We conclude that Ceacam1 regulates T cell activation, GVHD target organ damage, and numbers of donor T cells in lymphoid organs and GVHD target tissues. In recipients of allo-BMT, Ceacam1 may also regulate tissue radiosensitivity. Because of its expression on both the donor graft and host tissues, this suggests that targeting Ceacam1 may represent a potent strategy for the regulation of GVHD and GVT after allogeneic transplantation.
Recommended Citation
Lu, Sydney X; Kappel, Lucy W; Charbonneau-Allard, Anne-Marie; Atallah, Renée; Holland, Amanda M; Turbide, Claire; Hubbard, Vanessa M; Rotolo, Jimmy A; Smith, Marsinay; Suh, David; King, Christopher; Rao, Uttam K; Yim, Nury; Bautista, Johanne L; Jenq, Robert R; Penack, Olaf; Na, Il-Kang; Liu, Chen; Murphy, George; Alpdogan, Onder; Blumberg, Richard S; Macian, Fernando; Holmes, Kathryn V; Beauchemin, Nicole; and van den Brink, Marcel R M, "Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation." (2011). Department of Medical Oncology Faculty Papers. Paper 6.
https://jdc.jefferson.edu/medoncfp/6
PubMed ID
21760897
Comments
This article has been peer reviewed and is published in PLoS One 2011, 6(7). The published version is available at DOI: 10.1371/journal.pone.0021611. © Public Library of Science